194 related articles for article (PubMed ID: 17173035)
1. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin.
Garcia-Rodriguez C; Levy R; Arndt JW; Forsyth CM; Razai A; Lou J; Geren I; Stevens RC; Marks JD
Nat Biotechnol; 2007 Jan; 25(1):107-16. PubMed ID: 17173035
[TBL] [Abstract][Full Text] [Related]
2. Evolving an anti-toxin antibody.
Presta L
Nat Biotechnol; 2007 Jan; 25(1):63-5. PubMed ID: 17211401
[No Abstract] [Full Text] [Related]
3. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4.
Arndt JW; Jacobson MJ; Abola EE; Forsyth CM; Tepp WH; Marks JD; Johnson EA; Stevens RC
J Mol Biol; 2006 Sep; 362(4):733-42. PubMed ID: 16938310
[TBL] [Abstract][Full Text] [Related]
4. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A.
Razai A; Garcia-Rodriguez C; Lou J; Geren IN; Forsyth CM; Robles Y; Tsai R; Smith TJ; Smith LA; Siegel RW; Feldhaus M; Marks JD
J Mol Biol; 2005 Aug; 351(1):158-69. PubMed ID: 16002090
[TBL] [Abstract][Full Text] [Related]
5. Development and partial characterization of high-affinity monoclonal antibodies for botulinum toxin type A and their use in analysis of milk by sandwich ELISA.
Stanker LH; Merrill P; Scotcher MC; Cheng LW
J Immunol Methods; 2008 Jul; 336(1):1-8. PubMed ID: 18452945
[TBL] [Abstract][Full Text] [Related]
6. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains.
Dolimbek GS; Dolimbek BZ; Aoki KR; Atassi MZ
Immunol Invest; 2005; 34(2):119-42. PubMed ID: 15921155
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms.
Zhao H; Nakamura K; Kohda T; Mukamoto M; Kozaki S
Jpn J Infect Dis; 2012; 65(2):138-45. PubMed ID: 22446121
[TBL] [Abstract][Full Text] [Related]
8. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.
Marks JD
Mov Disord; 2004 Mar; 19 Suppl 8():S101-8. PubMed ID: 15027061
[TBL] [Abstract][Full Text] [Related]
9. Detection of botulinum neurotoxin A in a spiked milk sample with subtype identification through toxin proteomics.
Kalb SR; Goodnough MC; Malizio CJ; Pirkle JL; Barr JR
Anal Chem; 2005 Oct; 77(19):6140-6. PubMed ID: 16194071
[TBL] [Abstract][Full Text] [Related]
10. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3.
Webb RP; Smith TJ; Wright P; Brown J; Smith LA
Vaccine; 2009 Jul; 27(33):4490-7. PubMed ID: 19450643
[TBL] [Abstract][Full Text] [Related]
11. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
Dolimbek BZ; Aoki KR; Steward LE; Jankovic J; Atassi MZ
Mol Immunol; 2007 Feb; 44(5):1029-41. PubMed ID: 16647121
[TBL] [Abstract][Full Text] [Related]
12. Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody.
Midelfort KS; Hernandez HH; Lippow SM; Tidor B; Drennan CL; Wittrup KD
J Mol Biol; 2004 Oct; 343(3):685-701. PubMed ID: 15465055
[TBL] [Abstract][Full Text] [Related]
13. A sensitive sandwich enzyme immunoassay for free or complexed Clostridium botulinum neurotoxin type A.
Volland H; Lamourette P; Nevers MC; Mazuet C; Ezan E; Neuburger LM; Popoff M; Créminon C
J Immunol Methods; 2008 Jan; 330(1-2):120-9. PubMed ID: 18093612
[TBL] [Abstract][Full Text] [Related]
14. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.
Mullaney BP; Pallavicini MG; Marks JD
Infect Immun; 2001 Oct; 69(10):6511-4. PubMed ID: 11553596
[TBL] [Abstract][Full Text] [Related]
15. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.
Smith TJ; Lou J; Geren IN; Forsyth CM; Tsai R; Laporte SL; Tepp WH; Bradshaw M; Johnson EA; Smith LA; Marks JD
Infect Immun; 2005 Sep; 73(9):5450-7. PubMed ID: 16113261
[TBL] [Abstract][Full Text] [Related]
16. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.
Levy R; Forsyth CM; LaPorte SL; Geren IN; Smith LA; Marks JD
J Mol Biol; 2007 Jan; 365(1):196-210. PubMed ID: 17059824
[TBL] [Abstract][Full Text] [Related]
17. A peptide-based immunoassay for antibodies against botulinum neurotoxin A.
Atassi MZ; Dolimbek BZ; Deitiker P; Jankovic J; Aoki KR
J Mol Recognit; 2007; 20(1):15-21. PubMed ID: 16981247
[TBL] [Abstract][Full Text] [Related]
18. A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes.
Fan Y; Garcia-Rodriguez C; Lou J; Wen W; Conrad F; Zhai W; Smith TJ; Smith LA; Marks JD
PLoS One; 2017; 12(3):e0174187. PubMed ID: 28323873
[TBL] [Abstract][Full Text] [Related]
19. Nucleotide sequence and transcriptional analysis of the type A2 neurotoxin gene cluster in Clostridium botulinum.
Dineen SS; Bradshaw M; Karasek CE; Johnson EA
FEMS Microbiol Lett; 2004 Jun; 235(1):9-16. PubMed ID: 15158256
[TBL] [Abstract][Full Text] [Related]
20. Expression of an anti-botulinum toxin A neutralizing single-chain Fv recombinant antibody in transgenic tobacco.
Almquist KC; McLean MD; Niu Y; Byrne G; Olea-Popelka FC; Murrant C; Barclay J; Hall JC
Vaccine; 2006 Mar; 24(12):2079-86. PubMed ID: 16337316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
